Category: Biotechnology company
Quick infos Headquarters: Bothell, Washington, United States Trade prices Volume: Market Cap: 31.48B Prev closed: 133.4 Open: 135.75 High: 136.97 Low: 131.74 52 week low: 62.9 52 week high: 136.97 Dividends: No Dividends Next ER: February 11, 2021 After Market Closes
About the Company Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer.
Earnings History Date EPS / Forecast Revenue / Forecast February 4, 2021 October 29, 2020 3.5 / -0.41.06B / 330.18MJuly 30, 2020 -0.12 / -0.6278M / 256.73MBeat! July 14, 2020 - / -0.72- / 228.34MApril 30, 2020 -0.98 / -0.75234.51M / 211.01MBeat! view more
Historical Data Date Price Open High Low Vol Change ER Jan 15, 2021 185.75 178.95 186.55
177.38
1.36M 5.62% Jan 14, 2021 175.86 175.83 177.24
174.01
588.31K -0.47% Jan 13, 2021 176.69 179.76 180.13
176.12
653.74K -2.04% Jan 12, 2021 180.37 181.62 182.60
178.30
801.44K 0.74% Jan 11, 2021 179.04 177.75 181.57
177.31
490.50K 0.78% Jan 8, 2021 177.66 176.27 180.46
174.81
889.21K 0.74% Jan 7, 2021 176.36 168.26 176.91
166.91
1.20M 5.76% Jan 6, 2021 166.75 167.99 169.41
165.73
1.01M -1.33% Jan 5, 2021 169.00 170.93 172.01
167.40
1.21M 0.34% Jan 4, 2021 168.43 174.57 174.73
166.93
1.62M -3.83% view more
NASDAQ - Nasdaq Stock Market
More profiles and info about the company ISIN: US8125781026 CUSIP: 812578102 Founded:15 July 1997 Employees:890 News
FDA OKs Glaxo antibody-drug conjugate for last-line multiple myeloma seekingalpha.com Aug 6, 2020 8:55 pm
Seattle Genetics Reports Second Quarter 2020 Financial Results finance.yahoo.com Aug 6, 2020 4:02 pm
Seattle Genetics (SGEN) Q2 Earnings Beat, Adcetris Aids Sales finance.yahoo.com Aug 6, 2020 11:16 am
Seattle Genetics Achieves Milestone Payment Under Antibody-Drug Conjugate Collaboration with GlaxoSmithKline Triggered by BLENREP (belantamab mafodotin-blmf) FDA Approval finance.yahoo.com Aug 6, 2020 8:00 am Seattle Genetics EPS beats by $0.48, beats on revenue seekingalpha.com Jul 31, 2020 4:17 am Seattle Genetics Q2 top line up 27%, Padcev sales $57M seekingalpha.com Jul 31, 2020 4:09 am
Piper Sandler Downgrades Seattle Genetics, Says Visibility Limited On Value Creation finance.yahoo.com Jul 24, 2020 12:10 pm
What Can We Learn About Seattle Genetics' (NASDAQ:SGEN) CEO Compensation? finance.yahoo.com Jul 19, 2020 8:58 am
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2020 Financial Results on July 30, 2020 finance.yahoo.com Jul 9, 2020 8:00 am
Why Seattle Genetics Shares Climbed 48.7% in the First Half fool.com Jul 3, 2020 10:03 am
Seattle Genetics to Host Conference Call and Webcast on December 19, 2019 to Discuss PADCEVTM (enfortumab vedotin-ejfv) Approval finance.yahoo.com Jun 24, 2020 6:42 pm
Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treatment for Advanced Bladder Cancer finance.yahoo.com Jun 24, 2020 5:00 pm
Seattle Genetics Reports Fourth Quarter and Full Year 2019 Financial Results finance.yahoo.com Jun 24, 2020 4:02 pm Tech will drive change in health care throughout next decade bizjournals.com Jun 24, 2020 2:47 pm Seattle Genetics' stock rises on approval of bladder cancer drug marketwatch.com Jun 24, 2020 12:02 pm Seattle Genetics Soars on Cancer Drugs: Here's How to Play the Stock realmoney.thestreet.com Jun 24, 2020 11:45 am
Why This Leading Biotech Stock Just Added To Its 99% Gain This Year investors.com Jun 24, 2020 10:37 am
3 Nasdaq 100 Stocks With Excellent Upside Potential investopedia.com Jun 24, 2020 9:37 am Seattle Genetics Q2 Earnings Preview seekingalpha.com Jul 30, 2020 5:35 am European advisory group backs Glaxo antibody-drug conjugate for multiple myeloma seekingalpha.com Jul 24, 2020 10:41 pm This company doesn't provide a dividend.
Key Persons CEO : Clay B. Siegall, PhD CFO : Todd E. Simpson Talk about Seattle Genetics below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature. Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
investor.seattlegenetics.com If you are looking for News & events, Press Release, they are available on their Investors Relations site.
Homepage: seattlegenetics.com Consensus BUY 71 HOLD 29 SELL 0
If you want to help pay for server cost or for improving this tool. You can send it via Paypal . More features coming soon :)
Buy on Amazon Technical analysis is a collection of techniques designed to help you make trading decisions in securities markets. Technical Analysis For Dummies helps you take a hard-headed look at what securities prices are actually doing rather than what economists or analysts say they should be doing, giving you the know-how to use that data to decide whether to buy or sell individual securities.
A simple, straightforward guide to the fundamentals of technical analysis